Skip to main content
. Author manuscript; available in PMC: 2014 May 12.
Published in final edited form as: Pharm Res. 2011 Dec 3;29(6):1506–1517. doi: 10.1007/s11095-011-0625-0

Fig.6.

Fig.6

Effect of apigenin intake on VEGF and uPA in the serum; and MMP-2, MMP-9 and VEGF levels in the dorsolateral prostates of TRAMP mice. A Serum levels of VEGF and uPA were detected through ELISA assay as provided by the vendor’s protocol. Apigenin intake caused a dose-dependent decrease in serum VEGF and uPA levels. **P < 0.001, TRAMP apigenin versus TRAMP control (Kruskal-Wallis test). Bars ± SE of 6 mice B Protein expression of VEGF, MMP-2 and MMP-9 in the dorso-lateral prostate tissues of non-transgenic control, TRAMP control, TRAMP (20µg/day apigenin) and TRAMP (50µg/day apigenin) was detected by Western blotting. A significant decrease in VEGF, MMP-2 and MMP-9 protein expression was observed after apigenin intake. Representative data from two mice per group. Equal loading of protein in the lanes was confirmed by stripping the membrane and reprobing it with β-actin, a housekeeping protein. Details are described in ‘Materials and Method’ section.